KeyBanc Capital Markets maintains "Overweight" rating with $6 price target for GoodRx (GDRX).

From Yahoo Finance: 2025-06-23 12:34:00

GoodRx Holdings, Inc. (NASDAQ:GDRX) receives an “Overweight” rating from KeyBanc Capital Markets with a $6 price target. Analyst Scott Schoenhaus praises GoodRx’s strategic moves in response to the challenges of the retail pharmacy industry, including direct contracting strategies and adapting to events like Rite Aid’s bankruptcy.

GoodRx Holdings, Inc. (NASDAQ:GDRX) is exploring new opportunities within the pharmacy ecosystem involving manufacturers, retailers, PBMs, and consumers. While the re-acceleration of Monthly Active Consumers (MACs) may be delayed, the company aims to increase revenue per MAC through direct contracting relationships.

Analyst Scott Schoenhaus expresses confidence in CEO Wendy Barnes and her team’s ability to execute a growth plan, potentially leading to higher estimates for 2025. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform connecting various stakeholders to improve medication accessibility.

While GoodRx (GDRX) shows promise as an investment, some believe other AI stocks offer greater upside potential and less downside risk. For insights on a potentially undervalued AI stock with significant growth potential, check out the free report on the best short-term AI stock.

No disclosures.

Read more: KeyBanc Maintains Overweight Rating on GoodRx (GDRX)